After two years in the shadows, health stocks are back as a haven for investors navigating economic uncertainty.
Four top stocks have at least a 4% dividend and make sense for investors who may be worried about increased volatility in the ...
Half of all pancreatic cancer patients live less than a year after diagnosis. But researchers say there is potential for ...
Genitourinary Cancer Symposium 2025, held on 13-15 February, final results from the randomised, multicentre, double-blind, ...
Oppenheimer & Co. Inc. reduced its stake in Bristol-Myers Squibb by 8.1%, selling nearly 19,000 shares in Q4. The ...
In this video, Arvind N. Dasari, MD, MS, discussed the results of the CheckMate 8HW trial in which nivolumab and ipilimumab were compared with nivolumab monotherapy for microsatellite instability-high ...
From breakthrough treatments to AI-driven diagnostics, healthcare is evolving faster than ever. With increasing healthcare ...
Bristol Myers Squibb Co. closed 3.76% short of its 52-week high of $61.10, which the company achieved on January 27th.
Mary-Claire King, a groundbreaking innovator in genetics, received The National Academy of Sciences' most prestigious metal.
Patient advocacy group Patients for Affordable Drugs (P4AD) yesterday filed its fourth amicus brief defending the Biden ...
Viatris forecast annual revenue and profit below Wall Street estimates on Thursday, two months after the U.S. health regulator restricted imports from one of the drugmaker's key plants in India.
Even as President Donald Trump wages a very public fight against diversity, equity and inclusion (DEI) initiatives in the ...